An intragenic duplication within SIRPβ1 shows a dual effect over Alzheimer’s disease cognitive decline altering the microglial response

SIRPβ1 duplication increases the risk of dementia among mild cognitive patients while delaying cognitive progression of AD patients

The interstitial SIRPβ1 CNV consists of an ancestral duplication nowadays observed as a common insertion with an allele frequency of ≈0.2 in the general population. Previous reports estimated an r²=0.98 between the single nucleotide polymorphism rs2209313 allele T and the duplication allele of the SIRPβ1 CNV^{17, 21}. We independently confirmed these calculations taking advantage of the 1,000 Genomes Project data (Extended Methods) and therefore rs2209313 has been genotyped as a proxy of this structural variant. In order to explore whether this locus might affect AD risk, we performed a case-control association meta-analysis using the available datasets together with our own data from the DEGESCO consortium²². The combined results show that the rs2209313-T (duplication) allele has no significant effect over AD risk per se (OR_meta=0.980, p=0.06, Extended Data Table 1). Next, we explored the conversion risk from mild cognitive impairment (MCI) to AD, determined in the GR@ACE series, a subcohort of DEGESCO consortium which comprised 1,615 MCI patients who were followed up. We observed that MCI patients homozygous for the rs2209313 allele T-duplication (hereafter Dup/Dup) showed an increased likelihood to develop AD (Extended Data Table 2). Cerebrospinal fluid (CSF) taken at the moment of MCI diagnosis was analyzed, and we could observe that Dup/Dup patients showed increased phospho and total Tau/Aβ₄₂ ratios (Extended Figure 1). This coincides with the epidemiological data of a worse prognosis of MCI patients. To gain further insight into this effect, we took advantage of the GERALD series, another subcohort of DEGESCO which has magnetic resonance imaging (MRI) data taken at the moment of AD diagnosis. Patients homozygous for the duplication display less medial temporal atrophy (Scheltens visual ranking average of 4.5 vs 0.8) than those homozygous for the rs2209313 allele C-Wt (hereafter Wt/Wt) after adjusting by ApoE and hypertension (β = -0.605, p-value < 0.001) (Fig. 1a, 1b). Equivalent results were obtained with ANCOVA analysis (F_2,99 = 32.402, p-value < 0.001). In the same way, Dup/Dup patients show fewer White Matter Hyperintensities (WMH) than Wt/Wt patients after the same adjustments (Scheltens visual ranking average of 3.38 vs 1.0 for Total Periventricular Hyperintensities –TPVH–) (F_{2, 99} = 10.148, p-value = 0.044), suggesting lower Aβ₄₂-associated vascular damage (Fig. 1a, 1c). Since WMH is associated with hypertension, we split the GERALD series according to the hypertensive status (Extended Data Fig. 2). The results suggest that for both independent subgroups, Dup/Dup patients showed lower levels of vascular damage. The Mini-Mental State Examination (MMSE) scores were similar among the three groups (Figure 1d), suggesting that at the moment of AD diagnosis, the Dup/Dup patients presented equivalent cognitive functions with significantly less neural damage. This associates the SIRPβ1 Dup allele with a worse first-response to the initial stress of the CNS. We next examined whether this effect had a clinical correlation during the disease course. To this end, we conducted a prospective study evaluating the cognitive progression in the patients included in the GERALD series, and calculated the slope between the MMSE scores obtained upon recruitment and the first follow-up (FFU) (Extended Data Table 1). GERALD patients were then stratified according to their cognitive decline. Patients with a cognitive slope below the median were considered as slow progressors in contrast to the rapid ones. Binary logistic regression showed that AD patients bearing the SIRPβ1 Dup/Dup genotype also displayed a slower cognitive decline than the wild-type genotype after adjusting by APOE and MMSE score at diagnosis (Wald = 4.084, OR = 2.989, p-value = 0.043). Considering the entire series and stratifying them according to the SIRPβ1 genotype, we observed that Dup/Dup patients showed a slower cognitive decline expressed in MMSE scores month^-1 (average + SE: -0.09 + 0.09, n = 10) than the Wt/Wt patients (−0.13 + 03, n = 106). Linear regression did not reach statistical significance when adjusting by MMSE baseline and APOE genotype (Fig. 1e). Next, we replicated our longitudinal analysis in the GR@ACE cohort, an independent series which accounts with 4,656 AD patients, being the genetic effect statistically significant (β= 0.037, p-value = 0.013) (Fig. 1f). We should highlight this dual effect on the Dup/Dup genotype. First, the mutant allele was found to be a risk factor among MCI patients with a higher risk to convert AD. It was also associated with worse CSF biomarker levels and at a structural level, lower MTA atrophy and vascular damage generated the same loss of MMSE score than the Wt allele. In contrast, the duplication allele showed a protective effect over the cognitive decline in two independent series, suggesting a higher level of resilience of the CNS once the disease progresses. However, the best fitting genetic model in the case of the GR@ACE series was recessive rather than the codominant one observed in the GERALD series. One particular aspect that may explain this apparent discrepancy between both series is the difference in intervals of follow-up assessments. In the GR@ACE series, patients had their second visit 10.2 months after diagnosis, whereas in the GERALD it was at 18.2 months (Extended Data Table 3). Therefore, our independent observations might indeed be the same effect at two different timepoints (Fig. 1g).

• Download figure
• Open in new tab

Figure 1. Impact of SIRPβ1 rs2209313 in brain damage in AD patients.

Impact of rs2209313 allele T-duplication in AD evolution. a, coronal (upper row) view of MTA from three illustrative patients with the three rs2209313 genotypes and sagittal (lower row) WHM from three illustrative patients with the different possible genotypes. b, total periventricular hyperintensities from the Wt/Wt, n = 89; Wt/Dup, n = 51 and Dup/Dup, n=8 patients. c, medial temporal atrophy from the same patients. d, MMSE scores obtained at the moment of diagnosis. e, average MMSE slope values calculated as points of MMSE changed per month between the diagnosis and the first follow up (FFU) for the patients of GERALD (Wt/Wt, n = 106; Wt/Dup, n = 65 and Dup/Dup, n = 10) and f, GR@ACE series (Wt/Wt, n = 3,037; Wt/Dup, n = 1,429 and Dup/Dup, n = 190). g, effect of the mutation over the cognitive decline observed in both series, given that the GR@ACE series performed an earlier FFU than the one of the GERALD series. Bars represent average values + standard error (SE).

SIRPβ1 duplication enhances microglia response in the hippocampus of AD patients

Next, we focused on the impact of the SIRPβ1 genotype in the patient’s microglia. To address this question, we analyzed the expression of the microglial markers IBA1 and TMEM119 in a series of post-mortem human hippocampal samples at Braak V-VI (AD patients) compared to aged-matched control individuals (Braak II without neurological complains) (Fig. 2a and 2b). The results showed that the SIRPβ1 duplication correlated with an increased area occupied by IBA1 and TMEM119-possitive cells (Mann Whitney U-test, p-value = 0.03) (Fig. 2d and 2e), independent of the amyloid content. Confocal imaging revealed that AD brains (Braak V-VI) bearing the duplication allele showed an increased microglial response (Fig. 2c). Their amyloid plaques were found to be surrounded by more Iba1⁺ cells (Fig. 2f). With regard to the microglial expression signature, patients with the duplication allele exhibited approximately three-times higher levels of TREM2 (Fig. 2g), which correlates with an increased microglial response. When both activation (CD45, CSF1, CD74, PU.1) and homeostatic (CX3CR1, P2RY12, TMEM119) gene set scores were computed, we observed that the SIRPβ1 duplication increased both the degree of microglial activation (Fig. 2h) and homeostasis (Fig. 2i) after adjusting by ApoE genotype and Braak stage (Extended Data Table 4).

• Download figure
• Open in new tab

Figure 2. SIRPβ1 duplication affects plaque associated microglia in AD brains

Effect of SIRPβ1 variant on hippocampal microglia of AD patients. a, IBA1 and b, TMEM119 immunostaining of illustrative Wt/Wt and Wt/Dup from both Braak II and Braak V-VI subjects. c, confocal imaging of three Braak V-VI wild type patients and three Wt/Dup Braak V-VI subjects. A total of 29 and 47 plaques were analyzed respectively. Box plots in d and e show the IBA1⁺ and TMEM119⁺ area depending on the SIRPβ1 genotype. f, number of IBA1⁺ cells per plaque depending on the SIRPβ1 genotype. g, different average expression (+ SE) of TREM2. h and i represent the average gene set scores (+ SE) estimated for microglial activation and homeostasis, respectively

SIRPβ1 duplication allele changes the isoform landscape altering the Aβ₄₂ phagocytosis ability via TYROBP

To further examine the impact of the duplication allele on the SIRPβ1 protein structure, we characterized the exact CNV breakpoints. We analyzed a collection of unrelated subjects from the 1,000-genome project with different genetic backgrounds and low-coverage whole-genome sequencing data. We stratified the subjects according to their rs2209313 genotype and represented the coverage according to the hg38 reference genome. We observed a general homogeneity in the breakpoint location regardless of the population origin. Unfortunately, sequencing data did not allow us to clearly define the breakpoints at a nucleotide level (Extended Data Fig. 3). Thus, we analyzed the full sequence of bacterial artificial chromosomes (BAC) which spanned along the critical region. We observed that RP11-77C3 (Genebank AL138804.17) spanned along the entire SIRPβ1 locus, including rs2209313, and contained the ancestral haplotype (rs2209313 allele C-CNV Wt allele). In contrast, genome browser versions contain the complete form of the human genome, hence, containing the duplication allele. A local alignment allowed us to define the exact breakpoints of the duplication (Extended Data Fig 3e), and discovered that the structural variant involved exons 2-to-7.

We then explored GTEx RNA-seq data to determine the impact of the duplication allele on the different SIRPβ1 isoforms. SIRPβ1 is expressed in blood neutrophils, eosinophils and monocytes approximately 1,000-fold higher than in the microglia. Thus, whole-blood GTEx samples were analyzed. According to the ENSEMBL database, there are 12 different protein-coding isoforms. We focused on the four isoforms that were not annotated as “CDS 5’ incomplete” and had different coding sequences. As expected, the presence of rs2209313 allele T-duplication was found to modify SIRPβ1 isoform spectrum (Fig. 3a). Upon stratification by rs2209313 genotype, we found that the expression of ENST00000381605 (hereafter isoform 205) remained invariable regardless of the donor genotype. However, ENST00000262929 (isoform 201) and ENST00000279477 (isoform 202) were expressed preferentially when the duplication allele was present. On the contrary, ENST00000381603 (isoform 204) disappears with the duplication allele. The detailed analysis of the coding regions revealed that isoforms 201 and 204 contain a single extracellular Ig-like domain, whereas isoforms 202 and 205 display the canonical structure based on three Ig-like domains (Fig. 3b and 3c). Besides, we found two C-terminal regions which affected the TMD and therefore, their potential ability to contact with TYROBP. The amino acid sequence of the isoform 202 TMD (PLLIAFLLGPKVLLVVGVSVIYVY) is slightly different from that of Isoforms 201, 204 and 205 (PLLVALLLGPKLLLVVGVSAIYIC). The major differences are the change of L375 to F375, which does not alter the overall hydrophobic character but introduces a larger aromatic side chain in that position, and the change of C393 to Y393, that actually affects the polarity of the intracellular end of the TMD.

• Download figure
• Open in new tab

Figure 3. Impact of SIRPβ1 duplication

Impact of SIRPβ1 duplication. Panel a, Sashimi plot illustrating the Blood-derived RNAseq data available from GTEX according to the rs2209313 genotype. The impact of the duplication can be observed inside the critical region (in dashed red) over each SIRPβ1 isoform. Panel b, box plot representation of the relative mRNA abundance of each isoform in blood samples of healthy GTEX donors, according to the SIRPβ1 rs2209313 genotype. Panel c shows the comparison of the four different isoforms that are represented in panel d. Panel e shows the molecular dynamics results of analyzing TREM2 and SIRPβ1 isoforms 201 and 202 transmembrane domains in the presence of TYROBP’s. Panel f illustrates the B2H system used to quantify the transmembrane affinities. Panel g shows the Miller Units obtained after the beta-galactosidase assay of liquid cultures co-expressing the empty backbones (n = 4), and TYROBP with TREM2 (n = 6), SIRPβ1 Isoform 201 (n = 6) and SIRPβ1 isoform 202 (n = 6) TMDs. Bars represent the average Miller Units + SE. Panel h sows an illustrative Western Blot of a Aβ₄₂ phagocytosis assay of HEK293T cells co-transfected with different plasmid combinations. Lower line corresponds to the intracellular Aβ₄₂ while the upper lines correspond to either TREM2 or the different tagged SIRPβ1 isoforms transfected.

In order to explore the structural interaction of the TMD of SIRPβ1 isoforms and TYROBP, we have run Molecular Dynamics (MD) simulations of each dimer in a 1,2-palmitoyl-oleoyl-sn-glycero-3-phosphocholine (POPC) bilayer. We also included TREM2 TMD in the analysis to allow potential comparisons. These TMDs are mainly hydrophobic with a single charged amino acid located in the middle region of the helical structure (K186 and K380 in TREM2 and SIRPβ1, respectively, and D50 in TYROBP) (Fig. 3e, Extended Data Videos 1-3) that interact to create a stable hydrogen bond in all dimers. The orientation of the two domains is however different because of the presence of P379 in the SIRPβ1 isoforms, which introduces a kink right above K380. Also, the positions of K380 in SIRPβ1 and K186 in TREM2 are at slightly different depth into the bilayer, being K186 closer to the extracellular end of the helix, whereas K380 and D50 in TYROBP are at a similar membrane depth. In order to adopt an appropriate angle and distance to form the hydrogen bond between K380 and D50, the helices of SIRPβ1 in the dimer reorient from an almost parallel conformation to a tilted one. This suggests an uneven interaction of the TYROBP-SIRPβ1 depending on the TMD sequence. It is important to point out that in our simulations, SIRPβ1 lacks the large extracellular domain that may potentially restrict the conformation and orientation of the TMD within the lipid bilayer. Taking this into account, we observe a more stable interaction of the TYROBP-SIRPβ1 TMD dimer of isoforms 201, 204 and 205, where the TMD helical axis remains mostly parallel to the membrane normal throughout the simulation, than with the TMD of isoform 202, where the largely tilted orientation may not be reachable in the presence of the extracellular domain.

In order to explore this hypothesis, we cloned the different TMDs together with the membrane-anchoring pf3 N-terminal tag in-frame with the Adenylate Cyclase T18 and T25 domains to perform a membrane-anchored two hybrid analysis (B2H) (Fig. 3f). A first qualitative B2H examination revealed that the TREM2 TMD was more efficient in binding TYROBP than SIRPβ1 TMD. This was evidenced by a more intense X-gal staining of the overnight cultures containing both plasmids (Extended Fig. 4). For a more exhaustive characterization, we performed induced liquid culture β-galactosidase assays, which exhibit a wider dynamic range than the semiquantitative B2H. We observed that the transmembrane interaction between TYROBP and TREM2 TMDs is maximal, with an average of 903 Miller Units (MU), in contrast to the negative control (84 MU). TMD from SIRPβ1 isoform 201 (identical to 204’s and 205’s) was less efficient to contact TYROBP’s TMD (111 MU). As expected by the MD assays, TMD from isoform 202 was highly inefficient in contacting TYROBP’s TMD (94 MU), almost indistinguishable from the negative control (Fig. 3g).

Next, SIRPβ1 flag-tagged isoforms were co-transfected together with TYROBP in HEK293T culture cells (Extended methods). As a positive control, cells co-transfected with plasmids expressing TREM2 and TYROBP were used. Transfectants were then challenged to oligomeric Aβ₄₂ in order to evaluate their phagocytosis capacity. Two hours after the challenge, intracellular Aβ₄₂ content was determined (Fig. 3h). As expected, HEK293T cell line co-expressing TREM2 and TYROBP gained the ability to phagocyte Aβ₄₂ oligomers. SIRPβ1 isoforms 201 and 205 also allowed the HEK293T cells to phagocyte oligomeric Aβ₄₂. However, SIRPβ1 isoforms 202 and 204 did not. These data first demonstrate that Aβ₄₂ is a ligand of SIRPβ1, although in a clear isoform-dependent manner.

GERALD

We studied 196 patients with Alzheimer-type dementia attending the Memory Clinic of the Andalusian Institute for Neuroscience in Málaga, Spain. All patients had to meet the criteria of AD according to the benchmarks set forth by the National Institute on Aging Alzheimer’s Association workgroups ³⁴ Patients were clinically defined in stages 4, 5 and 6 of the Global Deterioration Scale³⁵. Patients who had any evidence suggestive of vascular dementia (VaD), such as focal neurological signs, abrupt deterioration or stepwise progression of cognitive deficits; those with focal vascular lesions (such as hematomas), strokes, normal pressure hydrocephalus; significant neurologic antecedents, such as brain trauma, brain tumors, epilepsy or inflammatory disease; those with serious systemic diseases such as hypothyroidism or chronic renal failure; those with serious psychiatric disorders, substance abuse or developmental anomalies; those who had severe behavioral or communicative issues which would make clinical or MRI examination difficult or those without a reliable informant, were excluded from the study. To avoid the possibility of misclassification of the diagnosis between AD and VaD, we excluded any patient who met the standard criteria for the diagnosis of VaD developed by the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l’Enseignement en Neurosciences. All participants underwent APOE genotyping. Information on demographic and clinical characteristics was collected basally: gender, age, educational level, AD diagnosis, personal and family history, personal psychiatric history, general medication, and antidementia drugs. Cognitive functioning was assessed using the Folstein Mini-Mental State Examination. Cognitive progression was assessed by calculating the slope between the MMSE score obtained at recruitment and the first follow-up.

GR@ACE

To conduct this research, we recruited 4,656 Spanish individuals; specifically 1,140 sporadic AD patients diagnosed by Neurologists as possible or probable AD in accordance with NINCDS-ADRDA criteria³⁴, 1,209 controls with unknown cognitive status from the general population, and 121 neuropsychologically healthy elderly controls who were screened for the absence of cognitive impairment using a structured interview including the neurological mental status examination, category fluency test, and MMSE. Epidemiological data of an initial subset of these series, DNA extraction, and APOE genotyping procedures have been previously described³⁶. Ethnicity was Caucasian in AD patients as well as in general population controls. Those individuals with age at onset below 65 years of age were considered as early-onset AD cases.

rs2209313 Genotyping

Genome-wide association studies meta-analysis on rs2209313 were obtained from the summary file from plink, obtained from different massive genotyping platforms. rs2209313 data from GR@ACE series was extracted from a previous GWAS using the Axiom 815K Spanish Biobank Array³⁷, the GERALD series was obtained using specific Taqman probe (Cat. Number 4351379, ThermoFisher Scientific, Massachusetts, USA).

Brain magnetic resonance imaging

MRI data were acquired on a 1.5 or 3.0 Tesla General Electric Signal scanner. Images were rated by an independent experienced neurologist who was blinded to the clinical data, including cognitive test results and NPI scores. White matter hyperintensities (WMH) and medial temporal atrophy (MTA) were assessed at the moment of diagnosis. WMH and MTA were evaluated as described below. Fluid attenuated inversion recovery and T1-weighted imaging were performed. The extent of WMH severity was rated visually on axial fluid-attenuated inversion recovery images using the Scheltens^{38, 39} visual rating scale for WMH. Frontal periventricular hyper-intensities, occipital periventricular hyper-intensities and lateral periventricular hyper-intensities were each rated on a scale of 0 (no hyper-intensities) to 2 (severe and profuse hyper-intensities), totaling up to a highest possible total score (TPVH) score of 6. In the same way, frontal deep subcortical hyper-intensities, parietal deep subcortical hyper-intensities, temporal deep subcortical hyper-intensities and occipital deep subcortical hyper-intensities were each rated on a scale of 0 (no hyper-intensities) to 6 (severe and profuse hyper-intensities), totaling up to a highest possible total deep subcortical hyper-intensities score of 24. Changes in the basal ganglia, which consist of the caudate, putamen, globus pallidus, thalamus, internal capsule, were considered as white matter lesions and were rated on a scale of 0 (no hyper-intensities) to 30 (severe hyper-intensities). Infratentorial lesions, which consist of cerebellum, midbrain, pons and medulla oblongata, were rated on a scale of 0 (no hyper-intensities) to 24 (severe hyper-intensities). The total WMH score for each patient was the sum of the four scaled ratings. MTA was measured using the Scheltens visual rating scale for MTA.20 The grade of MTA severity was rated visually on coronal T1-weighted and or fluid-attenuated inversion recovery images. Left MTA and right MTA volumes were each rated on a scale of 0 (no atrophy) to 4 (severe atrophy). The total MTA score for each patient was the sum of the two scaled ratings.

Statistical analysis

For Hardy-Weinberg equilibrium analysis and case control studies, the Institute of Human Genetics (https://ihg.helmholtz-muenchen.de/ihg/snps.html) were used. All polymorphisms included in downstream analysis showed call rates >0.95 and Hardy-Weinberg equilibrium (HWE) (p-value > 0.05). For quantitative analysis IBM SPSS version 25 was used (IBM Corporation, Armonk, New York, USA). Non-normally distributed data were represented using scatter-plots with the median and interquartile range (GraphPad Prism 8.0.1). Two group data were compared by Mann-Whitney U-test. The significance was set at 95% of confidence. To explore association between SIRPβ1 and brain structural imaging measurements we conducted two analysis of covariance (ANCOVA) with MTA and WMH scores as dependent variables. In case of multiple comparisons, Bonferroni’s correction was used. To adequately control their potential confounding role we controlled for HTA and ApoE. A stepwise binary logistic regression analysis, adjusting for MMSE score at diagnosis and ApoE, was fitted to assess associations of SIRPβ1 with cognitive progression. For this purpose, the MMSE slope score was subdivided by median score into those with high or low cognitive decline slope. The Hosmer and Lemeshow’s goodness-of-fit test was applied.

Alternative splicing analysis

We obtained transcript expression (transcripts per million, TPM) of SIRPβ1 (chr20:1,561,385-1,620,061, reverse strand) in the hippocampus (n = 165) and whole blood (n = 670) from the V8 release of the Genotype-Tissue Expression (GTEx) Project (dbGaP accession phs000424.v8.p2)1. In GTEx, RNA-seq reads are aligned to the human reference genome (build hg38/GRCh38) with STAR2 v2.5.3a, based on the GENCODE v26 annotation. Transcript-level quantifications are obtained with RSEM3 v1.3.0. We also retrieved the genotype at rs2209313 (chr20:1618496, C/T) in the same donors. We restricted our analysis to 4 protein coding transcripts with complete coding sequence (without evidence of 3’ or 5’ end truncation, according to Ensembl): ENST00000279477 (ENST00000568365 has identical CDS), ENST00000381605, ENST00000381603, and ENST00000262929. We assessed the difference in mean transcript expression between genotypes at rs2209313 using the two-sided Wilcoxon Rank-Sum test. We employed Benjamini-Hochberg false discovery rate (FDR) for multiple testing correction, setting the significance level at FDR = 0.05. We represented the distribution of transcript expression (log₁₀(TPM+1) for each tissue, transcript, and genotype group at rs2209313 as boxplots. Sample sizes for each tissue and genotype group are the following: blood CC (n = 426), CT (n = 215), TT (n = 29). In boxplots, the box represents the first to third quartiles and the median, and the whiskers indicate ± 1.5 × interquartile range (IQR). All the analyses were performed using R v4.0.3.

Immunohistochemistry analyses

Human hippocampal autopsy specimens were obtained from the Neurological Tissue Bank of IDIBAPS-Hospital Clinic (Barcelona, Spain). The utilization of post-mortem human samples was approved by the biobank and local ethic committees following Spanish legislation. Subjects were selected on the basis of post-mortem neuropathological examination and clinical data, and all cases were scored for Braak tau pathology. Samples (Extended Data Table 5) included cognitively normal subjects and demented AD patients. For morphological studies, hippocampal regions were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PB) for 24-48h, cryoprotected in sucrose, stored at -80ºC, sectioned (30 µm thickness) on a freezing microtome and serially collected in 0.1 M phosphate buffer saline (PBS) and 0.02% sodium azide. Free-floating sections were first heated for general antigen retrieval (80ºC for 20 min in 50 mM citrate buffer at pH 6.0). Then, endogenous peroxidase was inhibited (3% hydrogen peroxide/ 3% methanol in PBS, pH 7.4 for 20 min) and nonspecific staining was avoided by treating with 5% goat serum (Sigma-Aldrich) in PBS. Sections were incubated with the primary antibody over 24-72 hours at room temperature. The antibodies used in this study were: anti-Iba1 rabbit polyclonal (1:1000 dilution, FUJIFILM Wako Pure Chemical Corporation), and anti-TMEM119 rabbit polyclonal (1:500 dilution, Sigma-Aldrich). Tissue-bound primary antibody was then detected by incubating with the corresponding biotinylated secondary antibody (1:500 dilution, 70 min, Vector Laboratories) and streptavidin-conjugated horseradish peroxidase (1:2000, 90 min, Sigma-Aldrich). The peroxidase reaction was visualized with 0.05% 3-3-diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich) and 0.01% hydrogen peroxide in PBS. Sections were mounted on SuperFrost Plus™ Adhesion slides (Thermo Scientific), air dried, dehydrated in graded ethanol, cleared in xylene and coverslipped with DPX mounting medium (BDH Laboratories). Sections from control and diseased brains were assayed simultaneously using the same batches of solutions to minimize variability in immunolabeling conditions and the specificity of the immune reactions was controlled by omitting the primary antisera.

For double immunofluorescence staining, sections were incubated sequentially with anti-IBA1 goat polyclonal (1:2000 dilution, Abcam) and anti-amyloid fibrils (OC, 1:5000 dilution, Merck Millipore) followed by the corresponding Alexa 488/568 secondary antibodies (1:1000 dilution, Invitrogen) for 1 hour at room temperature. Subsequent nuclear staining (DAPI dye, Sigma-Aldrich) was performed, and sections were mounted on SuperFrost Plus™ Adhesion slides and coverslipped with 0.01M PBS containing 50% of glycerin and 3% of triethylenediamine (DABCO, Sigma-Aldrich). Treatment with an autofluorescence eliminator reagent (Merck Millipore) following the manufacturer’s recommendations was also performed. Immunofluorescent sections were examined under a confocal laser microscope (Leica SP8). Images are presented as maximum intensity projection of a z-stack with 1 µm steps.

Microglial loading was defined as the percentage of positive area stained with Iba1 (total myeloid cells) or TMEM119 (endogenous microglia) in relation to the total area of the analyzed region. Virtual images of Iba1 or TMEM119 immunostained sections were acquired using the fully automated digital microscopy system dotSlide (Olympus VS120) connected to an Olympus BX61VS optic microscope coupled with a high-resolution digital color camera (VC50 Olympus). The virtual images of the whole tissue sections were digitized at 40x magnification producing virtual images with a resolution of 0.173 μm/pixel and an average image size of 34213 pixel x 46480 pixel. Images from Braak V-VI hippocampus (including dentate gyrus and CA1-4) were then acquired using the Olyvia 2.6 image viewer software (Olympus) (image size: 1654 pixel x 877 pixel; pixel size: 28.34 pixel/cm). Digital images (2 sections/individual, n=5-6) were processed using the Visilog 6.3 (Noesis) image analysis system. The Iba1-or TMEM119-immunopositive signal within the selected brain region was converted into 8-bit gray scale, and immunostained microglial cells were identified by a threshold level mask. With the intensity threshold, only pixels with a staining intensity above a certain value in the intensity range scales (0-255) were visualized. A fixed threshold level (ranging between 170-180) was maintained throughout the image analysis of all sections from the same individual brain for uniformity.

To analyze the number of IBA1-positive cells surrounding amyloid plaques, double IBA1/OC immunofluorescence sections stained with DAPI were used. Amyloid plaques from Braak VI hippocampus were randomly selected (29-47 plaques, n=3-4 individuals) and z-stack confocal images were acquired with 63X 1.4 NA objective and 1 µm steps. All optical sections of the z-stack were quantified and plaque-associated Iba1 cells (including a 20µm-extra radius from the plaque edge) were counted.

Total RNA extraction

Total RNA were sequentially extracted, from human hippocampal tissue, using TRIsure Isolation Reagent (Bioline) (100□mg tissue/1□ml TRIsure Isolation Reagent) and purified by RNasy Mini Kit (Qiagen) following manufacture recommendations⁴⁰. RNA integrity was determined by RNA Nano 6000 (Agilent) (RIN: 4.95 ± 1.4). RNA was quantified using Nanodrop 2000 (Thermo Fischer).

Retrotranscription and quantitative real-time RT-PCR

Reverse transcription (RT) (4□μg of total RNA as template) was performed with High Capacity cDNA Archive Kit (Applied Biosystems). For real time qPCR, 40□ng of cDNA were mixed with 2× Taqman Universal Master Mix (Applied Biosystems) and 20× Taqman Gene Expression assay probes (Applied Biosystems). Quantitative RT-PCR (qPCR) was done using Taqman probes (Applied Biosystems). The different cDNAs were mixed with Taqman Universal Master Mix (Applied Biosystems) and Taqman Gene Expression assay probes. The quantitative PCR reactions (qPCR) were done using an ABI Prism 7900HT (Applied Biosystems). For activation or homeostatic set score, the expression of CD45 (Hs04189704_m1),d45 CSFsf1 (Hs00174164_m1), CDd74 (Hs00269961_m1) and PUu.1 (Hs02786711_m1) or CX3CRx3cr1 (Hs01922583_s1), P2RYry12 (Hs01881698_m1) and TMEMmem119 (Hs01938722_u1) were determined, respectively. Results were always expressed using the comparative double-delta Ct method where ΔCt values represent GAPDH normalized expression levels. Gene set score was calculated as described⁴¹.